Cover Image
市場調查報告書

Lixte Biotechnology Holdings, Inc.:產品平台分析

Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251686
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Lixte Biotechnology Holdings, Inc.:產品平台分析 Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 34 Pages
簡介

Lixte Biotechnology Holdings, Inc.是臨床階段的製藥公司。該公司著重於癌症和血管疾病等治療藥的藥物研發。

本報告提供Lixte Biotechnology Holdings, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Lixte Biotechnology Holdings, Inc.的基本資料

  • Lixte Biotechnology Holdings, Inc.概要
  • 主要資訊
  • 企業資料

Lixte Biotechnology Holdings, Inc.:R&D概要

  • 主要的治療範圍

Lixte Biotechnology Holdings, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Lixte Biotechnology Holdings, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Lixte Biotechnology Holdings, Inc.:藥物簡介

  • LB-100
  • LB-102
  • LB-201
  • LB-205
  • LB-300 Series
  • LB-400 Series

Lixte Biotechnology Holdings, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Lixte Biotechnology Holdings, Inc.:最近的開發平台趨勢

Lixte Biotechnology Holdings, Inc.:暫停中的計劃

Lixte Biotechnology Holdings, Inc.:企業發表

Lixte Biotechnology Holdings, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07300CDB

Summary

Global Markets Direct's, 'Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2015', provides an overview of the Lixte Biotechnology Holdings, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lixte Biotechnology Holdings, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lixte Biotechnology Holdings, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lixte Biotechnology Holdings, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lixte Biotechnology Holdings, Inc.'s pipeline products

Reasons to buy

  • Evaluate Lixte Biotechnology Holdings, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lixte Biotechnology Holdings, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lixte Biotechnology Holdings, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lixte Biotechnology Holdings, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lixte Biotechnology Holdings, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lixte Biotechnology Holdings, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lixte Biotechnology Holdings, Inc. Snapshot
    • Lixte Biotechnology Holdings, Inc. Overview
    • Key Information
    • Key Facts
  • Lixte Biotechnology Holdings, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Lixte Biotechnology Holdings, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Lixte Biotechnology Holdings, Inc. - Pipeline Products Glance
    • Lixte Biotechnology Holdings, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Lixte Biotechnology Holdings, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Lixte Biotechnology Holdings, Inc. - Drug Profiles
    • LB-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LB-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LB-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LB-205
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LB-300 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LB-400 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lixte Biotechnology Holdings, Inc. - Pipeline Analysis
    • Lixte Biotechnology Holdings, Inc. - Pipeline Products by Target
    • Lixte Biotechnology Holdings, Inc. - Pipeline Products by Route of Administration
    • Lixte Biotechnology Holdings, Inc. - Pipeline Products by Molecule Type
    • Lixte Biotechnology Holdings, Inc. - Pipeline Products by Mechanism of Action
  • Lixte Biotechnology Holdings, Inc. - Recent Pipeline Updates
  • Lixte Biotechnology Holdings, Inc. - Dormant Projects
  • Lixte Biotechnology Holdings, Inc. - Company Statement
  • Lixte Biotechnology Holdings, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lixte Biotechnology Holdings, Inc., Key Information
  • Lixte Biotechnology Holdings, Inc., Key Facts
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Indication, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Stage of Development, 2015
  • Lixte Biotechnology Holdings, Inc. - Monotherapy Products in Pipeline, 2015
  • Lixte Biotechnology Holdings, Inc. - Phase I, 2015
  • Lixte Biotechnology Holdings, Inc. - Preclinical, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Target, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Route of Administration, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Molecule Type, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Lixte Biotechnology Holdings, Inc. - Recent Pipeline Updates, 2015
  • Lixte Biotechnology Holdings, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Lixte Biotechnology Holdings, Inc. - Pipeline by Top 10 Indication, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Stage of Development, 2015
  • Lixte Biotechnology Holdings, Inc. - Monotherapy Products in Pipeline, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Top 10 Target, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Lixte Biotechnology Holdings, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top